MedTrace Logo

A Study of Duloxetine in Elderly Generalized Anxiety Disorder

NCT01118780 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 291

Last updated 2013-09-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and efficacy of duloxetine versus placebo in elderly patients suffering from generalized anxiety disorder (GAD).

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Duloxetine

Administered by mouth, daily for 10 weeks

DRUG

Placebo

Administered by mouth, daily for 10 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States
  • Argentina
  • Austria
  • Canada
  • Germany
  • Mexico
  • Poland
  • Puerto Rico
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01118780 on ClinicalTrials.gov